Payton Nyquvest, CEO of Numinus Wellness Inc (TSE:NUMI) (OTCMKTS: NUMIF), met with us to discuss the company’s two upcoming clinical trials with MDMA and psilocybin. Numinus Wellness Inc is a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies.
Oregon Pushes Interest In Naturally Derived Psilocybin
Numinus’ phase one proprietary psilocybin extract, known as NBI0-01, will be in one of the two clinical trials. It is naturally derived, and this may be fortunate in the wake of legalization laws such as in Oregon.
Nyquvest says, “I mentioned Oregon, which if you if you look at those regulations, legal, natural psilocybin, they’ve clearly spelled out that they’re not looking for [synthetic]. Not only they’re not looking for, but they’re not going to be approving synthetic psilocybin as it is right now. So there’s a really a very, very strong interest in natural psilocybin.”
The Difference Between Natural And Synthetic Psilocybin
When it comes to therapeutics, synthetics may just not be as ‘complete.’
“Natural psilocybin or psilocybin is something that occurs within psilocybin-containing fungi,” says Nyquvest. “And, you know, Mother Nature has been developing that product for a very long time. And one of the things that we see within natural psilocybin containing fungi is there’s other compounds that potentially have therapeutic benefit that exist with fungi – well known compounds like melatonin, serotonin, and cysteine, all the way to previously undiscovered compounds, potentially, that have therapeutic benefit.”
Numinus Ready To Produce MDMA For Treatment Of PTSD
“I feel like I’m probably a broken record on here talking about the maps results,” he confesses, “but just to reiterate, their Phase Three, over 80% of participants saw significant clinical reduction in their symptoms with MDMA for treatment resistant post traumatic stress disorder, and 67% no longer met the PTSD criteria. So essentially a cure for PTSD, and again, with people with treatment-resistant PTSD.”
Nyquvest says MAPS anticipates being able to legally treat with MDMA by 2023 in the US, and Numinus, working closely with MAPS for all this time, stands to benefit. “It’s going to be crucial for maps to be able to sell drug and distribute drug to companies or to practitioners that have the training that are familiar with the product, who can start to get it into market in the most low-risk way possible.”
Nyquvest adds, “…we sort of set ourselves up as a sort of the provider of choice in with MAPS, you know, there’ll be some others as well. But it gets us very familiar with the protocol with the therapy and setting up sort of all of the necessary distribution channels, which obviously, with our licensing out of our laboratory, we can be a drug product distributor, as well. … It gets us as a very easy first choice for MAPS when the therapy is approved, and starting to set up that necessary infrastructure in Canada, and now as we as we look to expand into the US, south of the border as well.”
Watch the full interview in the video above for more on what investors should know about the market space, and actions taken by Health Canada.
* In accordance with an executed agreement between The Dales Report and Numinus Wellness, The Dales Report is engaged with the aforementioned on a 12-month contract for $10,000 per month, with the purpose of publicly disseminating information pertaining to Numinus Wellness via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer.